Major Depressive Disorder (MDD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Major Depressive Disorder (MDD) Market Outlook

Thelansis’s “Major Depressive Disorder (MDD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Major Depressive Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Major Depressive Disorder (MDD) Overview

Major depressive disorder (MDD), also known as Depression, is a severe medical condition that disrupts various aspects of a person's life, including mood, behavior, thought processes, and physical well-being. While sadness and grief are normal responses to life's challenges, depression represents a more intense and prolonged state of emotional distress. There are also other related conditions, such as bipolar disorder (manic-depressive illness) and dysthymia. Bipolar disorder is characterized by alternating episodes of depression and mania. During manic episodes, individuals may experience extreme and inappropriate "high" emotions that can lead to risky and destructive behaviors. Dysthymia, on the other hand, exhibits symptoms similar to those of major depressive disorder but typically persists over a longer duration. The decline in hippocampal function is believed to play a role in depression by inhibiting the hypothalamic-pituitary-adrenal (HPA) axis, potentially contributing to the hypercortisolemia observed in depressed individuals. Furthermore, individuals with depression often exhibit elevated levels of pro-inflammatory markers such as C-reactive protein (CRP), interleukin (IL)-6, IL-1, and tumor necrosis factor-alpha (TNF-α).

• According to research, the prevalence of major depressive disorder (MDD) differs significantly across geographies, including the US (7.1%, 16.2 M) and Japan (4.7%, 5.0 M). In the US, MDD sufferers were more likely to be women than non-sufferers and were significantly younger (ps<0.05).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: